ImmuneКристагенCrystagen Lingual

Crystagen

Commercial Khavinson 'short peptide' immune bioregulator · chemistry UNVERIFIABLE · single-record evidence

Crystagen is a commercial 'short peptide' immune bioregulator sold within the Khavinson / St. Petersburg Institute of Bioregulation and Gerontology supplement line — and it is one of the few entries in this library where the most honest thing we can say is that we cannot confirm what it is. Its claimed amino-acid sequence could not be verified against any primary chemical database: there is no PubChem entry for 'Crystagen' as a compound or a substance, and the candidate sequences that circulate commercially don't map to a Crystagen-labeled chemical record. Worse, the vendors themselves disagree on the basics — some describe Crystagen as a three-amino-acid peptide (a tripeptide, often given as Glu-Asp-Pro), others as a four-amino-acid peptide (a tetrapeptide), and these are mutually inconsistent claims with no primary source behind any of them. So this page deliberately does not assert a sequence, formula, molecular weight, or CAS number, because none could be confirmed. The scientific evidence is equally thin: a search of PubMed for 'Crystagen' returns exactly one record — a Russian-language paper (English abstract only) from the Khavinson group that groups Crystagen with other short peptides and claims it 'activates B-cells' in the aging spleen. There is no independent, non-Khavinson, English-language clinical literature on it at all. The efficacy figures and detailed mechanisms (heat-shock-protein induction, cytokine modulation) that appear in marketing copy could not be tied to any verifiable primary source. The honest framing is heavy skepticism: a marketed longevity/immune supplement whose core chemical identity cannot be confirmed and whose efficacy rests on a single research school's single paper. The unverifiability is the key finding, and we state it plainly rather than papering over it with vendor specifics.

The short version

Crystagen is sold as an immune-system 'bioregulator' — one of a family of short-peptide supplements tied to the Russian Khavinson research program. The unusual and important thing about this entry is that we genuinely cannot confirm what Crystagen is made of. There is no record for it in the main chemical database (PubChem), under either of its product categories, and the sequences that sellers attach to it don't actually match any chemical record labeled 'Crystagen.'

The sellers don't even agree with each other. Some describe Crystagen as a three-amino-acid peptide; others call it a four-amino-acid peptide; the specific letters they give don't line up across sources. Because none of these claims traces back to a primary scientific source, this page does not state a sequence, chemical formula, molecular weight, or CAS number for Crystagen — asserting one would mean repeating an unverified vendor claim as if it were fact.

The research picture is just as thin. A search of the scientific literature turns up exactly one paper that even names Crystagen — a Russian-language study (with only an English summary) from the originating Khavinson group, which lumps it together with other short peptides and claims it 'activates B-cells' in the aging spleen. There is no independent, outside confirmation of any of its claimed effects, and the impressive-sounding efficacy numbers in marketing material can't be traced to a real study. The honest bottom line: treat Crystagen with heavy skepticism. Its identity is unconfirmed and its evidence amounts to a single paper from one school.

Molecular identity

Specs

Molecular formula: Unverified — not asserted
Molecular weight: Unverified — not asserted
CAS number: Unverified — none found

Sequence: Unverified — not asserted (vendors disagree: tripeptide EDP vs tetrapeptide; no primary source)PubChem PUGREST.NotFound; conflicting vendor claims
Class: Commercial Khavinson 'short peptide' / 'Cytogen' immune bioregulator (supplement)SPIBG commercial line (CITED)
PubChem CID: None — no CID exists for 'Crystagen'PubChem PUGREST.NotFound (compound)
PubChem SID: None — no substance record existsPubChem PUGREST.NotFound (substance)
Monoisotopic mass: Unverified — not asserted (no confirmed structure to compute from)No primary record
Molecular target: Unverified — the single primary record claims only that it 'activates B-cells' in the aging spleen; HSP/cytokine mechanisms in vendor copy are unsourcedPMID 28976144 (Chervyakova 2014; Russian)
Half-life: Not established (no pharmacokinetics; chemical identity itself unconfirmed)Not established
Peer-reviewed literature: Exactly one PubMed record names Crystagen (PMID 28976144; Russian, English abstract only)PubMed esearch (verified 2026-05-30)
Regulatory status: NOT FDA-approved; sold as a dietary supplement / 'Cytogen' bioregulator; Western grey-market onlyAbsence of FDA record; commercial sources (CITED)

Plain English

Mechanism

Crystagen is positioned within the Khavinson 'short peptide bioregulator' framework, which proposes that very short peptides can enter cells and influence gene expression in a tissue-specific way. Within that framework, Crystagen is presented as an immune-system regulator.

The single primary record that names it groups Crystagen with other short peptides (such as Vilon and Thymogen) as having immunoprotective effects in the aging spleen, and makes one specific claim: that Crystagen 'activates B-cells of the immune system' — while noting it does not cause cell renewal in the aging spleen. That is essentially the entire peer-reviewed mechanistic claim available.

Other, more elaborate mechanisms that appear in commercial copy — epigenetic gene-expression regulation, heat-shock-protein induction, cytokine modulation — could not be tied to a verified peer-reviewed primary source in our research and should be regarded as unverified vendor claims. And because Crystagen's chemical identity itself is unconfirmed, any mechanism attributed to it rests on an unusually shaky foundation: it is hard to be confident about how a molecule works when the molecule isn't even definitively identified.

Sources:PMID 28976144

Why people reach for it

Potential benefits

Crystagen is sold as an immune-system bioregulator — here is what draws people to it, framed with the heavy skepticism a compound of unverifiable chemistry and single-paper evidence demands.

The immune/spleen slot in a Khavinson routine — Crystagen is the line's immune-assigned 'short peptide,' so people building a tissue-by-tissue bioregulator protocol reach for it as the immune piece — a positioning, not a demonstrated effect.
A B-cell-activation research story — Its single peer-reviewed mention claims it 'activates B-cells' in the aging spleen, which is the one narrow research hook people point to — though it comes from a single Khavinson-group paper with no independent confirmation.
An aging-focused, course-based supplement — Used the way the rest of the Cytogen line is used — short periodic courses aimed at immune resilience in aging — appealing to people already invested in the bioregulator approach.
Points toward the immune levers that do work — The most defensible reason to engage with its immune framing is that it points at immune support at all — and the proven levers there (zinc sufficiency, vitamin D, protein, sleep) vastly outweigh a product whose identity can't even be confirmed.

Sources:PMID 28976144

What people reach for Crystagen for, based on how it is marketed and used — NOT proven outcomes. Crystagen's chemistry is unverifiable and its evidence is a single paper, so none of these are demonstrated effects or medical claims.

Implied timing

Best time to dose

Implied best time

Anytime (consistent)

Time of day isn't critical for Crystagen — pick a consistent daily time within the course and hold it.

Crystagen's chemical identity is unconfirmed and it has no pharmacokinetics — no half-life, no absorption data — so there is nothing to time a dose against. Day-to-day consistency is the only lever.
As an immune-positioned peptide, a mild evening lean is reasonable on the logic that immune consolidation and repair run overnight — but that is a soft rationale, not a Crystagen finding, and any consistent time is equally defensible.
If it is cycled alongside other Khavinson-line peptides, fixing it to the same daily slot is the simplest way to keep the course consistent.

No study establishes an ideal time of day for Crystagen — there is no pharmacokinetics, and the chemistry itself is unconfirmed, so nothing can be reasoned from the molecule. This is a consistency recommendation. As a general rule peptide dosing lands in the midday-to-evening window; for Crystagen any consistent time works, with at most a mild evening lean.

Sources:PMID 28976144

How to run it

Dosing & protocol

Crystagen is sold commercially as an oral or sublingual capsule product; as a grey-market injectable research peptide, vendors list subcutaneous use — but no dose is verified. The ranges and schedule below are vendor convention only, sourced from commercial copy and community practice, not from any clinical trial or published dosing study. Read this as a map of how the product is typically used in research circles — not a validated prescription, and explicitly not an endorsement of a compound whose chemistry cannot be confirmed.

Vendor convention only — not trial-proven, and chemistry is UNVERIFIABLE. Crystagen has no human clinical trial, no published pharmacokinetics, and no confirmed chemical identity. Every number here is unverified vendor and community convention. The product's identity and purity from grey-market sources are entirely unassured.

Dose — vendor convention only, unverified

These figures are taken directly from vendor product copy; they cannot be verified against any clinical study because none exists.

Route:: Subcutaneous injection (research-peptide form) or sublingual/oral capsule (retail supplement form). The on-page calculator and these practical cards address subcutaneous use — that is the injectable-research-compound form and the route consistent with the rest of this library.
Vendor dosing — UNVERIFIED:: Vendors typically describe cycles of 100–300 mcg per injection (or equivalent oral/sublingual capsule dose), given once daily for 10–30 day courses. These figures are vendor copy without a primary source and cannot be treated as evidence-backed. No dose is asserted by this site.
Why unverified:: The single PubMed record naming Crystagen is a mechanistic review, not a dosing trial. There is no dose that can be extracted from the scientific literature.

Subcutaneous administration

If using the injectable research form, the practical injection choices are site, rotation, and timing.

Injection site:: The abdomen (staying a couple of inches clear of the navel), the love-handle area, or the outer thigh. Rotate sites between doses so one spot is not used repeatedly — that prevents local irritation and fatty lumps (lipohypertrophy).
Measuring the dose:: Drawn on a U-100 insulin syringe from the reconstituted vial. Using the standard mix (10 mg vial + 2 mL BAC water = 5,000 mcg/mL): 100 mcg = 2 IU · 200 mcg = 4 IU · 300 mcg = 6 IU. The calculator does this live for any vial size.
Time of day:: No timing advantage has been published for Crystagen specifically — see Best time to dose above. Time of day isn't critical; a consistent daily time matters more than the exact hour, with at most a mild evening lean on immune-rhythm logic.
Food window:: Subcutaneous administration is independent of meals. The oral supplement form is typically taken on an empty stomach per vendor directions, though no study supports this claim either.

Cycle & washout

The Khavinson bioregulator family is conventionally used in short, repeated courses rather than continuous daily use.

Vendor cycle:: 10–30 day courses, one to two times per year — this is the standard Khavinson-line commercial pattern, drawn from product literature rather than clinical research.
Washout:: No published washout period exists for Crystagen. Community practice mirrors the broader Khavinson-line convention: 1–3 month break between courses. There is no data behind this interval.
Honest note:: Short-pulse cycling for bioregulators is a Khavinson-school doctrine, not an independently validated principle. The convention reflects the originating research group's framework, not multi-center trial data.

Reconstitution at a glance

Mixing math only — for the injectable research form. The calculator does this live.

Mixing:: 10 mg vial + 2 mL bacteriostatic water = 5,000 mcg per mL. On a 100-unit (1 mL) insulin syringe: 100 mcg = 2 IU · 200 mcg = 4 IU · 300 mcg = 6 IU · 500 mcg = 10 IU.
Why these numbers are rough:: Because no verified dose exists, these syringe conversions are provided purely for vial-math reference — not as a dosing recommendation. The calculator adjusts for any vial size.

Sources:PMID 28976144

Substrate the signal needs

Nutritional cofactor precision

Crystagen's sole claimed effect is immune — it is positioned as activating B-cells in the aging spleen. The honest cofactor angle is therefore the nutritional substrate that ordinary immune function runs on. The three groups below are reasoned from general immune-nutrition biochemistry applied to Crystagen's proposed immune role. They are not Crystagen cofactor studies — none exist. Read each as: 'if this peptide does anything immune, here is what the immune system needs to do it well.'

Reasoned from general immune-nutrition biochemistry — not a Crystagen study. Supplement doses are well-established community ranges for immune support, independent of any specific peptide. Crystagen's own evidence is a single unverified paper; these cofactors are the more defensible investment.

Amplify — zinc, vitamin D, selenium (immune-activation substrate)

Three nutrients the immune system cannot function without, and the most direct parallel to Crystagen's claimed B-cell / immune-activation positioning.

Zinc — headline cofactor:: Zinc is essential for normal immune and T-cell function — one of the most firmly established facts in nutritional immunology. Deficiency measurably blunts immune responses; repletion restores them. Any peptide claiming immune activation is acting on a system that runs poorly when zinc is low. 15–30 mg zinc picolinate or bisglycinate daily. If running longer than 4 weeks, pair with 1–2 mg copper bisglycinate to prevent copper depletion.
Vitamin D:: Low vitamin D status is consistently associated with impaired immune defense in observational data. Vitamin D receptors are expressed on nearly every immune cell type, including B-cells — the cell Crystagen claims to activate. Dose to a blood level in the sufficient range; most adults need 2,000–5,000 IU daily to reach it. Test first if possible.
Selenium:: Selenium is required for selenoprotein synthesis, including glutathione peroxidase enzymes that protect immune cells from oxidative stress during an active immune response. 100–200 mcg selenomethionine daily. Do not exceed 400 mcg/day — the therapeutic window is narrow.

Supply — protein and vitamin C (antibody and collagen substrate)

Immune cells — especially the B-cells Crystagen targets — are protein-intensive. Adequate intake is the prerequisite the rest of the immune stack sits on.

Protein:: Antibodies are proteins; B-cell proliferation is protein-intensive; immune repair is protein-intensive. Inadequate total protein is a primary driver of immune insufficiency in older adults (Crystagen's core target population). Target ≥1.2–1.6 g/kg bodyweight daily from whole-food sources. This is not a supplement — it is the foundation.
Vitamin C:: Vitamin C supports immune cell function, enhances neutrophil motility, and is depleted rapidly during active immune responses. 500–1,000 mg daily in split doses for maintenance; higher acute doses (2–3 g/day) are used conventionally during active illness. Well-established immune-nutrition, no Crystagen-specific data.

Mitigate — minimal cost, foundational sleep

Crystagen's side-effect profile is uncharacterized (grey-market, unverified identity), so mitigate means addressing the single biggest immune suppressor that costs nothing.

Sleep:: 7–9 hours of quality sleep per night is the most potent immune-support intervention in human biology. Cytokine release, B-cell activity, and immunological memory consolidation all happen predominantly during sleep. No supplement — including Crystagen — overrides chronic sleep deficit. Prioritizing sleep is both the most honest and most defensible cofactor recommendation for any immune-positioning compound.
Purity risk awareness:: Because Crystagen's chemical identity is unconfirmed and sourcing is grey-market, the 'cofactor' that matters most is knowing what is actually in the product. Independent third-party COA testing for a product with no confirmed molecular standard is limited, but it is still more information than nothing.

Combinations + timing

Stacking notes + timing windows

Crystagen is positioned as an immune-system activator within the Khavinson bioregulator family. The most natural pairings are other Khavinson-line immune peptides — but any such stack carries every caveat on this page doubled. A more defensible immune-modulating partner with independent peer-reviewed data is Thymosin Alpha-1. All combinations below are community convention only.

High-skepticism speculation — any stack built on Crystagen is stacking an unverified compound on top of another. Crystagen has unconfirmed chemistry and a single-paper evidence base; pairing it with anything compounds that uncertainty. These pairings are user-reported community convention within the Khavinson research tradition, not studied combinations. Doses are vendor convention, not clinical evidence.

Crystagen + Thymalin or Thymogen (Khavinson immune family)

The community convention within the Khavinson bioregulator line — pairing immune-targeted peptides from the same family across complementary immune-tissue roles.

Why it works — as claimed:: Within Khavinson's framework, Thymalin (thymus gland extract peptides) and Thymogen (short thymus-derived peptide, Glu-Trp) are positioned as thymus-regulatory and T-cell-supporting; Crystagen is positioned as B-cell-activating in the spleen. The combination is supposed to address both arms of adaptive immunity from their respective source tissues. This is the originating school's logic — not demonstrated in a comparative clinical study.
The protocol:: Community practice follows individual Khavinson-line cycle schedules — 10–30 day courses per product, staggered or overlapping depending on user preference. Doses are each product's vendor convention: no verified dose exists for any of these compounds. Flag: this is three products with unverified chemistry and single-school evidence running concurrently.
Outcome:: Aimed at broad immune restoration in aging — the Khavinson program's declared goal. There is no independent clinical evidence of benefit from any combination of these bioregulators. The combination is by-family-association, not by demonstrated synergy.

Crystagen + Thymosin Alpha-1

The more defensible immune-modulating pairing — Thymosin Alpha-1 has actual peer-reviewed human data, which Crystagen entirely lacks.

Why it works:: Thymosin Alpha-1 (Tα1) is a 28-amino acid thymic peptide with documented immune-modulating activity — it enhances T-cell maturation and dendritic cell function, and has been used clinically in hepatitis B and some cancer-adjuvant contexts. Pairing it with Crystagen is speculative (Crystagen contributes no verified mechanism), but Tα1 at least brings documented immune activity to the combination. Different proposed immune levers — B-cell activation (Crystagen) vs. T-cell and innate modulation (Tα1) — though Crystagen's lever is unverified.
The protocol:: Thymosin Alpha-1: community convention is ~1.5 mg subcutaneously twice weekly, run in 4–12 week courses. Crystagen alongside at vendor convention dosing and cycle length. The honest note: Tα1's most rigorous independent trial (BOOST, chronic hepatitis B) showed null primary endpoints. Verify the Thymosin Alpha-1 page for current evidence framing.
Outcome:: Reached for by users seeking broader immune modulation — combining a compound with thin evidence (Crystagen) and one with mixed-but-real evidence (Tα1). Tα1 is the active partner here by any evidential measure.

Crystagen + Vilon or Vladonix (Khavinson immune/vascular)

Extended Khavinson-stack community practice — adding vascular or broad-longevity bioregulators to the immune pair.

Why it works — as claimed:: Vilon (Lys-Glu) is positioned as a vascular bioregulator; Vladonix as immune and cardiovascular. Within the Khavinson framework these are 'layered' across tissues — immune, spleen, vascular — on the theory that aging bioregulator deficits are system-wide. The same skepticism applies: both compounds have unverified chemistry and single-school evidence bases.
The protocol:: Individual product cycles per Khavinson-line convention (10–30 days each, 1–2× per year). The most commonly discussed order in community forums is to run Crystagen and one immune-family peptide first, then add a vascular or longevity peptide in a separate course. All doses are vendor convention only.
Outcome:: This is the broadest speculative stack in the Khavinson family — 'whole-system bioregulator restoration' as the vendor framing describes it. Zero independent clinical evidence exists for any combination. The foundational immune-nutrition cofactors in the section above are a more defensible starting point.

Reconstitution math

Reconstitution calculator

Calculated for a 1 mL U-100 insulin syringe (100 units/mL).

Peptide per vial

BAC water added

Desired dose

Units per dose

Draw to this mark on a U-100 syringe

Volume per dose: 0.2 mL
Doses per vial: 10
Concentration: 5 mg/mL

One vial lasts

Daily: 10 days
Every other day: 20 days
5×/week: 14 days

Research use only. Not for human consumption. Outputs are reference values based on research literature — verify all measurements independently.

From the studies

Side effects from research

There is no verified safety literature for Crystagen, so no side-effect profile can be reported. It is marketed as a well-tolerated supplement, but that is vendor framing rather than independent safety evidence.

The deeper issue is that, with the substance's identity unconfirmed, even a clean-sounding safety claim is hard to interpret — you cannot meaningfully characterize the safety of a product whose composition isn't established. The safety of Crystagen specifically is uncharacterized.

Grey-market sourcing adds purity and identity risk on top of that fundamental uncertainty. The fair summary: no documented serious harm, but also no real safety evidence and no confirmed idea of what is actually in the product.

As reported in literature

Research dosing ranges

There is no verified dosing or efficacy data for Crystagen — its chemistry is unconfirmed and exactly one PubMed record names it. The single row below summarizes that lone paper's qualitative claim; it is not a dosing study. Everything else circulating commercially (efficacy percentages, capsule cycles) is unverified vendor copy. No dose is asserted.

Dose	Route	Model	Outcome	Sources:
Not asserted	Not applicable (review)	Spleen short-peptide immunoprotection review — the ONLY record naming Crystagen (Chervyakova/Khavinson 2014, Russian, English abstract)	Qualitative claim only: Crystagen 'activates B-cells of the immune system' but does not cause cell renewal in the aging spleen; no sequence, no dose, single-school	PMID 28976144

Quick answers

Frequently asked

What is Crystagen made of?

We can't confirm. There is no PubChem record for 'Crystagen,' and vendors disagree — some call it a tripeptide (often given as Glu-Asp-Pro), others a tetrapeptide — with no primary source behind either. Because none of these claims can be verified, this page deliberately does not assert a sequence, formula, molecular weight, or CAS number for it.

How much research is there on Crystagen?

Almost none. A PubMed search returns exactly one record that names it — a Russian-language paper (English abstract only) from the originating Khavinson group, which claims Crystagen 'activates B-cells' in the aging spleen. There is no independent, non-Khavinson, English-language clinical literature on it.

Are the efficacy percentages I see online real?

They can't be verified. Specific efficacy figures and detailed mechanisms (heat-shock-protein induction, cytokine effects) that appear in marketing copy could not be tied to any verifiable primary source in our research, and should be treated as unverified vendor claims.

Why does this page refuse to list a sequence?

Because asserting one would mean repeating an unverified vendor claim as fact. The candidate sequences don't map to any Crystagen-labeled chemical record, and the vendors themselves contradict each other. The honest, accurate statement is that the chemistry is unverifiable — and we'd rather say that plainly than fabricate a false precision.

Should I be skeptical of Crystagen?

Strongly. Its chemical identity is unconfirmed, its evidence is a single paper from one research school, the marketed efficacy numbers can't be traced to a real study, and it isn't FDA-approved. That combination warrants heavy skepticism — the unverifiability is itself the key takeaway.

What is the recommended dose?

There is no verified dose. The vendor-convention figure circulating in community practice is 100–300 mcg per injection (or equivalent oral capsule) in 10–30 day courses, but this comes entirely from commercial product copy — not from any clinical study. No dose is asserted by this site.

Primary sources

References

PMID 28976144Chervyakova, Linkova, Chalisova, Khavinson et al., Adv Gerontol 2014 — molecular aspects of immunoprotective peptide activity in aging spleen (the only record naming Crystagen; Russian, English abstract)
PubChem PUGREST.NotFoundPubChem — name lookup for 'Crystagen' returns no compound and no substance record (chemistry unverifiable)

Research use only · Not medical advice · Updated 2026-06-01